TORONTO, May 2, 2024
/CNW/ - Andlauer Healthcare Group Inc. (TSX: AND) ("AHG" or the
"Company") today reported its financial results for the three-month
period ended March 31, 2024 ("Q1 2024").
Q1 2024 Summary
- Revenue totaled $161.1 million, a
decrease of 2.2% from $164.8 million
for the three-month period ended March 31, 2023
("Q1 2023");
- Operating income was $21.2
million, compared to $23.7
million in Q1 2023;
- Net income totaled $14.9 million,
or $0.35 per share (diluted),
compared to $16.5 million, or
$0.39 per share (diluted), in Q1
2023;
- Total comprehensive income was $20.5
million, compared to $16.3
million in Q1 2023;
- EBITDA1 totaled $39.6
million, compared to $40.5
million in Q1 2023; and
- EBITDA Margin1 was 24.6%, compared to 24.6% in Q1
2023.
"Aside from lower fuel surcharge revenue, our 2.2%
year-over-year decline in revenue was primarily attributable to two
factors. First, revenue in our U.S. truckload businesses reflects
depressed rates and our decision to focus on higher margin
business. Second, we had lower revenue in our Accuristix business
attributable to lower volumes from certain consumer health clients.
These declines were partially offset by organic growth in our
Canadian specialized transportation network," said Michael Andlauer, Chief Executive Officer of
AHG. "Looking ahead, we will continue to focus on revenue quality
in our U.S. truckload businesses and we believe that our recent
capacity expansion at our LSU facility
in Montreal will make a positive
contribution to our logistics and distribution business as the year
progresses. We expect continued growth in our Canadian specialized
transportation network."
"Today, we also published our inaugural sustainability report.
The report highlights our responsible business approach, which
starts and ends with our people – our
professional drivers, owner-operators, and teams working across our
network. Their commitment and passion are the engine of our success
and a key to our strong industry partnerships and stakeholder
relations. This report will serve as a baseline against which we
will measure our future progress for the communities we serve."
Selected Consolidated Financial Summary
|
Three months
ended
March 31,
|
|
($CAD 000s, except
per share
amounts)
|
2024
|
2023
|
Variance
|
Revenue
|
|
|
|
Logistics and
distribution
|
37,918
|
40,523
|
(6.4) %
|
Packaging
solutions
|
4,942
|
5,510
|
(10.3) %
|
Healthcare Logistics
segment
|
42,860
|
46,033
|
(6.9) %
|
Ground
transportation
|
106,388
|
108,260
|
(1.7) %
|
Air freight
forwarding
|
7,995
|
7,542
|
6.0 %
|
Dedicated and last
mile delivery
|
17,745
|
17,131
|
3.6 %
|
Intersegment
revenue
|
(13,850)
|
(14,192)
|
(2.4) %
|
Specialized
Transportation segment
|
118,278
|
118,741
|
(0.4) %
|
Total
revenue
|
161,138
|
164,774
|
(2.2) %
|
Operating
expenses
|
139,895
|
141,084
|
(0.8) %
|
Operating
income
|
21,243
|
23,690
|
(10.4) %
|
Net
income
|
14,923
|
16,528
|
(9.7) %
|
Foreign currency
translation adjustment
|
5,537
|
(200)
|
N/A
|
Total
comprehensive income
|
20,460
|
16,328
|
25.3 %
|
Earnings per share –
basic
|
$ 0.36
|
$ 0.39
|
($ 0.03)
|
Earnings per share –
diluted
|
$ 0.35
|
$ 0.39
|
($ 0.04)
|
Select financial
metrics
|
|
|
|
EBITDA1
|
39,592
|
40,469
|
(2.2) %
|
EBITDA
Margin1
|
24.6 %
|
24.6 %
|
--
|
Q1 2024 Financial
Results
Consolidated revenue for Q1 2024 decreased by 2.2% to
$161.1 million, compared with
$164.8 million in Q1 2023. The
decrease was primarily attributable to lower revenue in the
Company's US-based truckload business (Boyle Transportation and
Skelton USA) and Accuristix, and
lower fuel surcharge revenue, partially offset by organic growth in
the Company's Canadian specialized transportation product lines,
excluding fuel surcharge revenue.
Revenue for the healthcare logistics segment totaled
$42.9 million, a decrease of 6.9%, or
approximately $3.2 million, compared
with Q1 2023. The decrease reflects a 6.4% decline in the Company's
logistics and distribution product line revenue and a 10.3% decline
in packaging revenue. The decline in logistics and distribution
revenue was primarily attributable to lower outbound order handling
and transportation activities for certain Accuristix consumer
health clients. The decline in packaging revenue primarily reflects
the loss of one of the Company's packaging customers in Q1
2023.
Revenue in the specialized transportation segment totaled
$118.3 million, a decrease of 0.4%,
or approximately $0.5 million,
compared with Q1 2023. The decrease reflects a decline in US-based
truckload revenue and lower fuel surcharge revenue, partially
offset by organic growth in each of the Company's Canadian
specialized transportation product lines.
Ground transportation revenue for Q1 2024 was $106.4 million, a decrease of 1.7%, or
approximately $1.9 million, compared
with Q1 2023. The decrease is primarily attributable to a decline
in AHG's US-based truckload business, reflecting lower rates and
the Company's focus on revenue quality, as well as lower fuel costs
passed through to customers as a component of pricing compared to
Q1 2023. These factors were partially offset by organic growth in
the Company's Canadian ground transportation network. Ground
transportation revenue, excluding fuel, in the Company's Canadian
network increased by approximately 3.2%.
The $0.5 million increase in air
freight forwarding revenue in Q1 2024 compared to Q1 2023 reflects
a 2.3% year-over-year increase in weight shipped. The $0.6 million increase in dedicated and last mile
delivery revenue in Q1 2024 compared to Q1 2023 reflects continued
organic growth, partially offset by a reduction in fuel surcharge
revenue.
Cost of transportation and services was $82.5
million, or 51.2% of revenue,
compared with $84.2 million, or 51.1% of revenue, for Q1
2023. Lower fuel costs in line with decreases in revenue related to
fuel prices were partially offset by idle equipment costs in AHG's
US-based truckload businesses arising from a lower volume of loads
as the Company focused on revenue quality.
Direct operating expenses were $26.3 million, or 16.3% of revenue, compared with
$27.0 million, or 16.4% of revenue,
for Q1 2023. The decrease was primarily attributable to a reduction
in outbound order handling activities for Accuristix in line with
lower revenue.
Operating income totaled $21.2
million, a decrease of $2.4
million compared to Q1 2023. The decrease was primarily
attributable to reduced contributions from Boyle Transportation and
Skelton USA.
Net income was $14.9 million, or
$0.35 per share (diluted), compared
with $16.5 million, or $0.39 per share (diluted), in Q1 2023. Lower
segment net income before eliminations for AHG's specialized
transportation segment was primarily attributable to reduced
contributions from Boyle Transportation and Skelton USA, and lower segment net income from the
Company's healthcare logistics segment reflects reduced order
handling and transportation activity.
Total comprehensive income was $20.5
million compared to $16.3
million for Q1 2023. Total comprehensive income differs from
net income due to the acquisition of foreign operations (Boyle
Transportation and Skelton USA),
which resulted in a positive foreign currency translation
adjustment of $5.5 million in Q1 2024
compared to a negative foreign currency translation adjustment of
$0.2 million in Q1 2023.
Earnings before interest, taxes, depreciation and amortization
("EBITDA")¹ totaled $39.6 million
compared with $40.5 million for Q1
2023. The decrease was due to the factors discussed above and
primarily reflects lower contributions from the Company's US-based
truckload operations and reduced outbound order handling activities
for Accuristix, partially offset by organic growth in the Company's
Canadian specialized transportation network. EBITDA1
attributable to Boyle Transportation and Skelton USA was approximately $2.5 million lower in Q1 2024 compared to Q1
2023. EBITDA Margin¹ of 24.6% was unchanged from Q1 2023, as a
reduction in US-based truckload margins were offset by higher
margins in the Company's Canadian specialized transportation
network.
Dividend
The Company paid a dividend (encompassing the period from
January 1, 2024 to March 31, 2024) in the amount of $0.10 per subordinate voting share and multiple
voting share on April 15, 2024.
Subject to financial results, capital requirements, available
cash flow, corporate law requirements and any other factors that
AHG's Board of Directors may consider relevant, it is the Company's
intention to declare a quarterly dividend of $0.10 per subordinate voting share and multiple
voting share on an ongoing basis.
Shares Outstanding
On March 24, 2023, the Company
announced that the Toronto Stock Exchange had approved its notice
of intention to make a normal course issuer bid ("NCIB") for up to
a maximum of 1,856,857 of its subordinate voting shares, or
approximately 10% of its public float as of March 23, 2023, over the 12-month period
commencing on March 29, 2023. As at
March 31, 2024, 634,090 Subordinated Voting
Shares, or approximately 3% of AHG's public float, had been
purchased and cancelled pursuant to the NCIB. The NCIB was
terminated on March 28, 2024.
As at March 31, 2024, there were
19,483,920 subordinate voting shares and 21,840,000 multiple
voting shares issued and outstanding.
Financial Statements
AHG's unaudited interim condensed consolidated financial
statements and related Management's Discussion & Analysis
("MD&A") for Q1 2024 are available on the
Company's website at www.andlauerhealthcare.com and under
AHG's profile on SEDAR+ at www.sedarplus.ca.
Conference call and webcast
Michael Andlauer, Chief Executive
Officer, and Peter Bromley, Chief
Financial Officer, will host a conference call for analysts and
investors on Friday, May 3, 2024 at
8:30 a.m. (ET). To join the
conference call without operator assistance, you may register and
enter your phone number at: https://emportal.ink/43SbyuG to receive
an instant automated call back. Alternatively, you can dial (416)
764-8650 or (888) 664-6383 to reach a live operator that will join
you into the call.
You can access a live webcast of the call under the
Presentations & Events section of AHG's investor website
at:
https://andlauerhealthcare.com/andlauer-healthcare-presentations-events/
To access a replay of the conference call, dial 416-764-8677 or
(888) 390-0541, passcode: 534181 #. The replay will be available
until May 10, 2024. The webcast will be archived
on the Company's website following the conclusion of the call.
About AHG
AHG is a leading and growing supply chain management company
offering a robust platform of customized third-party logistics
("3PL") and specialized transportation solutions for the healthcare
sector. The Company's 3PL services include customized logistics,
distribution and packaging solutions for healthcare manufacturers
across Canada. AHG's specialized
transportation services in Canada,
including air freight forwarding, ground transportation, dedicated
delivery and last mile services, provide a one-stop shop for
clients' healthcare transportation needs. Through its complementary
service offerings, available across a coast-to-coast distribution
network, AHG strives to accommodate the full range of its
clients' specialized supply chain needs on an integrated and
efficient basis. The Company also provides specialized ground
transportation services, primarily to the healthcare sector, across
the 48 contiguous U.S. states.
For more information on AHG, please visit:
www.andlauerhealthcare.com.
Forward-looking Information
This news release contains forward-looking information and
forward-looking statements (collectively, "forward-looking
information") within the meaning of applicable securities laws.
Forward-looking information may relate to the Company's future
financial outlook and anticipated events or results and may include
information regarding the Company's financial position, business
strategy, growth strategies, addressable markets, budgets,
operations, financial results, taxes, dividend policy, plans,
objectives and expectations with respect to COVID-19. Particularly,
information regarding the Company's growth expectations,
performance, achievements, payment of dividends, prospects,
potential acquisitions, financial targets or outlook is
forward-looking information. In some cases, forward-looking
information can be identified by the use of forward-looking
terminology such as "plans", "targets", "expects", "budget",
"scheduled", "estimates", "outlook", "forecasts", "projection",
"prospects", "strategy", "intends", "anticipates", "believes",
"commencing" or variations of such words and phrases or statements
that certain actions, events or results "may", "could", "would",
"might", "will", "will be taken", "occur" or "be achieved". In
addition, any statements that refer to expectations, intentions,
targets, projections or other characterizations of future events or
circumstances contain forward-looking information. Statements
containing forward-looking information are not historical facts but
instead represent management's expectations, estimates and
projections regarding future events or circumstances. Such
forward-looking statements are qualified in their entirety by the
inherent risks, uncertainties and changes in circumstances
surrounding future expectations which are difficult to predict and
many of which are beyond the control of the Company.
Forward-looking information is necessarily based on a number
of opinions, estimates and assumptions, including but not limited
to those assumptions described under the heading "Cautionary Note
Regarding Forward-Looking Information" in the Company's MD&A
for Q1 2024. Forward-looking information is subject to known and
unknown risks, uncertainties, assumptions and other factors that
may cause the actual results, level of activity, performance or
achievements to be materially different from those expressed or
implied by such forward-looking information, including but not
limited to factors discussed under the heading "Risk Factors" in
the Company's annual information form dated March 5, 2024, which is available on the
Company's profile on SEDAR+ at www.sedarplus.ca. If any of these
risks or uncertainties materialize, or if the opinions, estimates
or assumptions underlying the forward-looking information prove
incorrect, actual results or future events might vary materially
from those anticipated in the forward-looking information.
Accordingly, investors should not place undue reliance on
forward-looking information, which speaks only as of the date made.
The forward-looking information contained in this news release
represents the Company's expectations as of the date of this news
release and are subject to change after such date and the Company
disclaims any intention or obligation or undertaking to update or
revise any forward-looking information whether as a result of new
information, future events or otherwise, except as required under
applicable securities laws.
(1) Non-IFRS Financial Measures
This news release
contains certain non-IFRS measures. These measures are
not recognized measures under IFRS, do not have a standardized
meaning prescribed by IFRS and are therefore unlikely to be
comparable to similar measures presented by other companies.
Rather, these measures are provided as additional information to
complement those IFRS measures by providing further understanding
of the Company's results of operations from management's
perspective. Accordingly, these measures should not be considered
in isolation nor as a substitute for analysis of the Company's
financial information reported under IFRS. AHG uses non-IFRS
measures including "EBITDA" and "EBITDA Margin". These non-IFRS
measures are used to provide investors with supplemental measures
of the Company's operating performance and thus highlight trends in
its core business that may not otherwise be apparent when relying
solely on IFRS financial measures. AHG also believes that
securities analysts, investors and other interested parties
frequently use non-IFRS measures in the evaluation of issuers. AHG
management also uses non-IFRS measures in order to facilitate
operating performance comparisons from period to period, to prepare
annual operating budgets and to determine components of
management compensation.
EBITDA
AHG defines EBITDA
as net income for the period before:
(i) income tax expense (recovery); (ii) interest income; (iii)
interest expense; and (iv) depreciation
and amortization.
AHG believes EBITDA is a useful measure to assess the
Company's financial performance because it provides a more relevant
picture of operating results by excluding the effects of expenses
that are not reflective of the Company's underlying business
performance.
EBITDA Margin
AHG defines EBITDA Margin as EBITDA divided by revenue.
EBITDA Margin represents a measure of the Company's profitability
expressed as a percentage of revenue.
AHG believes EBITDA Margin is a useful measure to assess the
Company's financial performance because it helps quantify the
Company's ability to convert revenues generated from clients into
EBITDA.
Reconciliation of EBITDA
($CAD
000s)
|
|
|
Three Months
Ended
March 31,
|
|
|
|
|
2024
|
2023
|
Net
income
|
|
|
|
14,923
|
16,528
|
Income tax
expense
|
|
|
|
5,445
|
5,847
|
Interest
expense
|
|
|
|
1,579
|
1,933
|
Interest
income
|
|
|
|
(695)
|
(599)
|
Depreciation and
amortization
|
|
|
|
18,340
|
16,760
|
EBITDA1
|
|
|
|
39,592
|
40,469
|
SOURCE Andlauer Healthcare Group Inc.